Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation

Francesca Patriarca, Benedetto Bruno, Hermann Einsele, Francesco Spina, Luisa Giaccone, Vittorio Montefusco, Miriam Isola, Chiara Nozzoli, Andrea Nozza, Fortunato Morabito, Paolo Corradini, Renato Fanin

Research output: Contribution to journalArticle

Abstract

We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR], 2.495; 95% confidence interval [CI], 1.770-3.517; P < .0001). Seven-year overall survival (OS) was 31% in the donor group and 9% in the no-donor group (HR, 1.835; 95% CI, 1.306-2.577; P < .0001). By multivariate analysis, chemosensitivity to salvage treatments and presence of a suitable donor were significantly associated with better PFS and OS. The long-term follow-up of this study confirms the significant PFS benefit and provides new evidence of an OS advantage for patients with MM who have a suitable donor and undergo allo-SCT. Allo-SCT should be considered as a treatment option in young relapsed patients with high-risk disease features after first-line treatment.

Original languageEnglish
Pages (from-to)406-409
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2018

Fingerprint

Autologous Transplantation
Multiple Myeloma
Tissue Donors
Recurrence
Stem Cell Transplantation
Disease-Free Survival
Salvage Therapy
Survival
Confidence Intervals
Histocompatibility Testing
Multicenter Studies
Multivariate Analysis
Retrospective Studies
Therapeutics

Keywords

  • Journal Article

Cite this

Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. / Patriarca, Francesca; Bruno, Benedetto; Einsele, Hermann; Spina, Francesco; Giaccone, Luisa; Montefusco, Vittorio; Isola, Miriam; Nozzoli, Chiara; Nozza, Andrea; Morabito, Fortunato; Corradini, Paolo; Fanin, Renato.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 2, 02.2018, p. 406-409.

Research output: Contribution to journalArticle

Patriarca, Francesca ; Bruno, Benedetto ; Einsele, Hermann ; Spina, Francesco ; Giaccone, Luisa ; Montefusco, Vittorio ; Isola, Miriam ; Nozzoli, Chiara ; Nozza, Andrea ; Morabito, Fortunato ; Corradini, Paolo ; Fanin, Renato. / Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 2. pp. 406-409.
@article{ebe16b92655d45ebb9e8491ed8440a56,
title = "Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation",
abstract = "We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91{\%}) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18{\%} in the donor group and 0{\%} in the no-donor group (hazard ratio [HR], 2.495; 95{\%} confidence interval [CI], 1.770-3.517; P < .0001). Seven-year overall survival (OS) was 31{\%} in the donor group and 9{\%} in the no-donor group (HR, 1.835; 95{\%} CI, 1.306-2.577; P < .0001). By multivariate analysis, chemosensitivity to salvage treatments and presence of a suitable donor were significantly associated with better PFS and OS. The long-term follow-up of this study confirms the significant PFS benefit and provides new evidence of an OS advantage for patients with MM who have a suitable donor and undergo allo-SCT. Allo-SCT should be considered as a treatment option in young relapsed patients with high-risk disease features after first-line treatment.",
keywords = "Journal Article",
author = "Francesca Patriarca and Benedetto Bruno and Hermann Einsele and Francesco Spina and Luisa Giaccone and Vittorio Montefusco and Miriam Isola and Chiara Nozzoli and Andrea Nozza and Fortunato Morabito and Paolo Corradini and Renato Fanin",
note = "Copyright {\circledC} 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = "2",
doi = "10.1016/j.bbmt.2017.10.014",
language = "English",
volume = "24",
pages = "406--409",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation

AU - Patriarca, Francesca

AU - Bruno, Benedetto

AU - Einsele, Hermann

AU - Spina, Francesco

AU - Giaccone, Luisa

AU - Montefusco, Vittorio

AU - Isola, Miriam

AU - Nozzoli, Chiara

AU - Nozza, Andrea

AU - Morabito, Fortunato

AU - Corradini, Paolo

AU - Fanin, Renato

N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR], 2.495; 95% confidence interval [CI], 1.770-3.517; P < .0001). Seven-year overall survival (OS) was 31% in the donor group and 9% in the no-donor group (HR, 1.835; 95% CI, 1.306-2.577; P < .0001). By multivariate analysis, chemosensitivity to salvage treatments and presence of a suitable donor were significantly associated with better PFS and OS. The long-term follow-up of this study confirms the significant PFS benefit and provides new evidence of an OS advantage for patients with MM who have a suitable donor and undergo allo-SCT. Allo-SCT should be considered as a treatment option in young relapsed patients with high-risk disease features after first-line treatment.

AB - We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR], 2.495; 95% confidence interval [CI], 1.770-3.517; P < .0001). Seven-year overall survival (OS) was 31% in the donor group and 9% in the no-donor group (HR, 1.835; 95% CI, 1.306-2.577; P < .0001). By multivariate analysis, chemosensitivity to salvage treatments and presence of a suitable donor were significantly associated with better PFS and OS. The long-term follow-up of this study confirms the significant PFS benefit and provides new evidence of an OS advantage for patients with MM who have a suitable donor and undergo allo-SCT. Allo-SCT should be considered as a treatment option in young relapsed patients with high-risk disease features after first-line treatment.

KW - Journal Article

U2 - 10.1016/j.bbmt.2017.10.014

DO - 10.1016/j.bbmt.2017.10.014

M3 - Article

C2 - 29032267

VL - 24

SP - 406

EP - 409

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -